According to most authors (1, 2, 11), probenecid acts by inhibiting tubular transport of organic acids in the kidney. The elevated serum concentrations of penicillin occurring after administration of probenecid were therefore attributed to inhibition of tubular secretion.
However, in 1968 Gibaldi and Schwartz (5) stated that probenecid leads not only to a decrease in renal elimination but also to a reduction of the apparent volume of distribution of a number of penicillins and cephaloridine in a one-compartment model, and both mechanisms were thought to be responsible for the higher serum concentrations observed during probenecid administration. The authors did not use data of their own, and it may be argued that some of the published data of others that they used were not really suitable for the kind of calculations required to prove their point.
In 1970 Gibaldi et al. published a study (4) on a two-compartment model, using pharmacokinetic parameters obtained in five patients receiving benzylpenicillin by the intravenous route. Their results led them to conclude that the ratio between the amounts of drug in the central and peripheral compartments were changed by probenecid in favor of the central compartment. The only explanation they offered for this phenomenon was a possible interference of probenecid with the penetration of benzylpenicillin into certain body compartments.
Because in our opinion the results obtained by Gibaldi et al. did not warrant their discouragement of the use of probenecid together with penicillin, we investigated the specific claim that probenecid would directly influence the volume of distribution of penicillin. For this purpose we chose patients lacking kidney function, because under this condition an indirect effect on the apparent volume of distribution by probenecid via a reduced elimination is excluded. The penicillin chosen was cloxacillin, because we were familiar with the pharmacokinetics of this drug in patients without renal function (9) .
MATERIALS AND METHODS
Patients. Five patients (aged 16 to 29 years) on chronic intermittent hemodialysis and one patient (65 years old) with a moderately diminished renal function (creatinin clearance, 24 ml/min) were included in this investigation. The study was carried out between hemodialysis periods with the patients lying in bed. All five hemodialysis patients had undergone a bilateral nephrectomy. Liver function tests were normal, and none of the patients had an abnormal body temperature.
Cloxacillin assay. Cloxacillin concentrations in the serum were measured by the agar plate diffusion method on phosphate peptone agar (pH 6.5) with Sarcina lutea ATCC 9341, according to Grove and Randall (6) with the modification of Mattie et al. (8) . The minimal serum concentration that could be assessed accurately was about 2.5 ug/ml. After collection, all samples were stored at -20 C. Determina- tions were performed within a week.
Administration of cloxacillin. After a loading dose of 1 g, cloxacillin (1 g of sodium salt [Orbenin] in vials for parenteral use) was administered to four of the patients by continuous infusion (Fig. 1 ). In three of these patients, who were on hemodialysis, cloxacillin was infused at a rate of 0.6 g/h for 4 h. For the fourth patient, the only one with a partially disturbed kidney function, the cloxacillin was infused at a rate of 1 The apparent volume of distribution of cloxacillin during the continuous infusion can be calculated with the following equation (10): (2) in which A, is the amount administered up to time t, V is the apparent volume of distribution, C, is the concentration at time t, K is the elimination rate constant, and fC' C -dt is the area under the serum concentration curve from time zero to time t. A linear relationship exists between A, and the righthand part of the equation; the slope is equal to V. Table 1 shows the calculated values of the apparent volume of distribution (V) of cloxacillin, given without or together with probenecid. The mean value for the elimination rate constant of cloxacillin in anuric patients (0.326/h) is in close accordance with the value we obtained in anuric patients after a single intravenous injection (9) . Tables 2 to 4 give the serum concentrations in each individual patient. DISCUSSION From the results of our study, we conclude that probenecid does not significantly change the apparent volume of distribution for cloxacillin in a one-compartment model in anuric patients. In this respect there seems to be no difference between continuous administration Because the administration of probenecid to healthy subjects leads in any case to higher It is also interesting that, in spite of the complete absence of kidney function, anuric patients show a significant reduction of the elimination. It is evident that probenecid diminishes not only the renal but also the extrarenal elimination. This phenomenon can possibly be explained by a blockade of the elimination by the liver. This possibility is supported by Fishman's (3) observation that probenecid reduces the ratio of the liver-to-serum concentration of benzylpenicillin in nephrectomized dogs. The uptake of other drugs by the liver, including rifamycin (7), is also decreased, leading to a slower elimination.
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